Last reviewed · How we verify
NCT03645304: PAIN
Postoperative Analgesic Efficacy of Continuous Wound Infusion After Laparoscopy
NA trial testing Ropivacaine in Benign Gynecologic Neoplasm in 66 participants. Status unknown.
3 April 2020
Quick facts
| Lead sponsor | Kangbuk Samsung Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 66 |
| Start date | 21 January 2019 |
| Primary completion | 3 April 2020 |
| Estimated completion | 3 April 2020 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Ropivacaine (ROPIVACAINE) — full drug profile →
- 0.9% saline group
- ON-Q Painbuster Silver Soaker
Conditions studied
- Benign Gynecologic Neoplasm — all drugs for Benign Gynecologic Neoplasm →
Sponsor
Kangbuk Samsung Hospital
Who can join
Adults 18 to 80, female only, with Benign Gynecologic Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Studies evaluating the effectiveness of continuous wound infusion (CWI) to manage postoperative pain following laparoscopy are markedly lacking. Especially, there was no study comparing CWI and placebo in treating gynecologic laparoscopy. Therefore, the investigators conducted this randomized, double-blind, placebo-controlled trial to investigate whether CWI of local anesthetics was an effective strategy for enhanced recovery after surgery (ERAS), compared with placebo in patients undergoing benign gynecologic laparoscopy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03645304
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ropivacaine
Trials testing the same drug.
- NCT07116343 — Intrapleural Ropivacaine Infusion in Cardiac Surgery · Phase 4 · recruiting
- NCT07209345 — Pre-emptive Scalp Infiltration With Low-dose Flurbiprofen and Ropivacaine for Postoperative Analgesia After Craniotomy · NA · recruiting
- NCT05642026 — INTERCOSTAL NERVE BLOCK: Efficacy of CINB for Patients With Multiple Rib Fractures · Phase 4 · recruiting
- NCT07013526 — Dexmedetomidine as Adjuvant for Suprazygomatic Maxillary Nerve Block in Children's Adenotonsillectomy · NA · not yet recruiting
- NCT06925789 — Influence of Standardized Perioperative Anesthetic, Analgesic Care on Outcome of Patients Undergoing Hip Fracture Surger · Phase 1 · withdrawn
Other Kangbuk Samsung Hospital trials
Trials by the same sponsor.
- NCT07396961 — Consistency of ASIS Line vs. Tuffier's Line for Lumbar Level Identification · not yet recruiting
- NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
- NCT06773585 — Investigations of Factors Associated With Treatment Response and Prognosis in Anxiety Disorders · not yet recruiting
- NCT06130137 — Gut Microbiome in People Living With HIV and HBV · not yet recruiting
- NCT05538741 — Hypotension After Anesthetic Induction with Remimazolam in Elderly · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03645304 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kangbuk Samsung Hospital
- Last refreshed: 8 August 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03645304.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing